Diagnosis and Reclassification of Myelodysplastic Syndromes and Acute Myeloid Leukemia: Comparison Between the 2016 WHO 4th and 2022 WHO 5th/ICC Classifications
Authors:
Open Access
- 1 July 2024
- journal article
- research article
- Published by Laboratory Medicine Online in Laboratory Medicine Online
- Vol. 14 (3) , 208-217
Abstract
Su Min Han, M.D., Sang Hyuk Park, M.D., Hyun-Ki Kim, M.D., Ji-Hun Lim, M.D., Joseph Jeong, M.D., Seon-Ho Lee, M.D.. Lab Med Online 2024;14:208-17. https://doi.org/10.47429/lmo.2024.14.3.208Keywords
This publication has 13 references indexed in Scilit:
- TP53 Mutational Status in Myelodysplastic Neoplasm and Acute Myeloid Leukemia: Impact of Reclassification By Who 2022 and ICC Criteria - a Korean Multi-Center StudyBlood, 2023
- AML classification in the year 2023: How to avoid a Babylonian confusion of languagesLeukemia, 2023
- Comparison of the International Consensus and 5th WHO edition classifications of adult myelodysplastic syndromes and acute myeloid leukemiaAmerican Journal of Hematology, 2023
- Comparison of the revised 4th (2016) and 5th (2022) editions of the World Health Organization classification of myelodysplastic neoplasmsLeukemia, 2022
- International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic dataBlood, 2022
- The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic NeoplasmsLeukemia, 2022
- Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndromeBlood, 2022
- ISCN 20202020
- Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromesNature Medicine, 2020
- Myelodysplastic SyndromesNew England Journal of Medicine, 2009